PTC Therapeutics (PTCT) PT Raised to $68 at JPMorgan, 'We believe the Sephience franchise will secure the next chapter of growth'
Tweet Send to a Friend
JPMorgan analyst Eric Joseph raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $68.00 (from $67.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
